Innovation and focus
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need.
Our vision is to transform how the pharmaceutical industry approaches the understanding and treatment of neurodegenerative disease such as Alzheimer’s Disease.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.
The NSB board brings a wealth of experience in biopharmaceuticals, commercial medical and corporate leadership.
NeuroScientific Biopharmaceuticals is backed by Mcrae Investments Pty Ltd and was founded by renowned businessman Harold Clough AO OBE.
Covance is NSB’s selected partner for preclinical studies, offering complete development solutions from preclinical to clinical to market.
Convance have managed over 3300 unique compounds and more than 500 IND/CTD programs in the last 5 years.
The renowned Lion’s Eye Institute is NSB’s partner for ophthalmology studies, bringing experience from several significant achievements, including:
• Developed the 1st artificial cornea
• Developed the 1st transgenic animal model for macular degeneration
• Glaucoma treatment recently acquired by global pharma Allergan
The goal of Menzies is “to perform internationally significant medical research leading to healthier, longer and better lives.”
Menzies has made significant research breakthroughs by contributing significantly to knowledge on prevention and treatment of diseases including multiple sclerosis, dementia and cancer.